WHO ICTRP trial
High Dose Methotrexate Pharmacokinetics, Pharmacogenomics, Adverse Effects and…
CTRI/2023/07/054865 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/07/054865 |
|---|---|
| Public title | High Dose Methotrexate Pharmacokinetics, Pharmacogenomics, Adverse Effects and Clinical Outcomes in Patients with Acute Lymphoblastic Leukaemia |
| Scientific title | A Pilot Study to Determine the Influence of Single Nucleotide Polymorphism on High Dose Methotrexate Pharmacokinetics, Adverse Effects and Clinical Outcomes in Patients with Acute Lymphoblastic Leukaemia in a North Indian Tertiary Care Hospital |
| Primary sponsor | PGIMER |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] |
| Interventions | Intervention1: Methotrexate: 2 ml Blood will be collected at 3 time points in each maintenance cycle who are on high dose methotrexate |
| Registration date | Jun 7, 2023 |
| Target size | 100 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: